CD44 and glioblastoma: We further performed in silico molecular docking of NSC765689 with the GBM oncogenes; GSK3β, β-Catenin, and STAT3, and the stem cell marker of CD44, to predict protein-ligand interactions, and results indicated that NSC765689 exhibited stronger binding affinities compared to its predecessor, LCC09, which was recently published by our laboratory, and proved to inhibit GBM stemness and resistance.